Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution (NCT05728879)

🧪 Interventions in This Study

• APR-TD011 (RLF-TD011) (COMBINATION_PRODUCT)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Dermatology CTU — Chicago, Illinois

📞 Contact the Study Coordinator

Phone: (312) 503-5944

Email: NUderm-research@northwestern.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cutaneous T Cell Lymphoma

• Characterization of the Microbiome in Cutaneous T Cell Lymphoma — Chicago, Illinois
• Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) — Tampa, Florida
• Photopheresis in Early-stage Mycosis Fungoides — New York, New York
• Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas — Ann Arbor, Michigan
• A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma — Boston, Massachusetts

Explore by condition: All Cutaneous T Cell Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.